The Next Innovation Divide Will Be Institutional

Governments across the world are spending aggressively on innovation. Artificial intelligence strategies, semiconductor subsidies, industrial policy packages, startup incentives, and digital modernization programs have become standard tools of economic competition. Yet despite the scale of this investment, relatively few countries consistently convert innovation spending into durable technological advantage.

The explanation is often framed in terms of capital, talent, or access to technology. But in Likhota’s view, the more decisive variable lies elsewhere: not in how much countries fund innovation, but in how effectively they organize it.

Likhota’s research, focused on U.S. innovation governance and institutional innovation systems, examines why some economies build structures capable of scaling innovation while others remain dependent on fragmented policy tools, short-term incentives, and politically visible but economically incomplete innovation agendas.

At the center of that argument is a simple but often overlooked point: innovation is still too often treated as a technology issue when, in practice, it is primarily an institutional one.

That distinction helps explain a problem economists have long described as the European Paradox: the difficulty of converting strong scientific research into globally dominant technology companies. In Likhota’s framework, the issue is not scientific quality alone. It is the friction between research, ownership, financing, regulation, procurement, and commercial scale.

That distinction is central to Likhota’s work on the American innovation system. Rather than treating U.S. technological leadership as the product of entrepreneurial culture alone, his analysis examines it as the outcome of institutional coordination — specifically, the way federal agencies, research institutions, public financing, commercialization systems, intellectual property rules, and long-cycle strategic planning are organized into a repeatable innovation architecture.

This is where his contribution becomes more specific than the broader policy consensus around innovation. The work does not simply argue that institutions matter. It traces how U.S. innovation capacity is built through coordination across federal research agencies, commercialization pathways, regulatory systems, and strategic industrial planning — turning innovation from a policy objective into an operational economic system.

This helps explain why the United States continues to outperform many economies attempting to replicate its innovation success.

In recent years, governments across Europe, Asia, and the Middle East have launched ambitious innovation programs backed by significant public investment. Many have funded strategic sectors, expanded industrial subsidies, and introduced national technology agendas. But in many cases, these efforts remain policy-heavy and system-light: rich in incentives, weak in institutional continuity.

Likhota’s analysis identifies this as one of the most persistent structural weaknesses in modern innovation policy. Governments often finance technology without building the institutional mechanisms required to absorb, coordinate, commercialize, and scale it. The result is innovation activity without durable innovation capacity.

The lesson is not that every country should reproduce the American model. It is that durable innovation requires complementary institutions that connect research funding, intellectual property protection, procurement, commercialization, venture financing, and industrial capacity over time, rather than relying on isolated programs.

The U.S. model, in this reading, offers a clearer example of how innovation becomes economically reproducible. Federal institutions such as the National Science Foundation and the National Institutes of Health build upstream scientific capacity. Agencies such as DARPA operate as strategic accelerators for high-risk technologies. Commercialization mechanisms, including the Bayh-Dole framework, reduce the distance between public research and private deployment. Programs such as SBIR and STTR create early-stage pathways between federally supported innovation and market execution. More recent instruments, including the CHIPS and Science Act, extend that institutional logic into strategic manufacturing and industrial resilience.

What emerges from that structure is a coordinated system for converting research into industrial capability, public investment into commercial scale, and technological development into strategic economic leverage.

That distinction is becoming more important as the global technology race shifts from invention to deployment. In semiconductors, artificial intelligence, biotechnology, and advanced manufacturing, the decisive advantage increasingly belongs not to the economies that generate promising technologies first, but to those capable of integrating them into production systems, capital structures, and long-cycle industrial strategies more effectively.

This is where innovation policy most often breaks down. Governments can subsidize research, finance startup ecosystems, and announce strategic priorities. But without institutional mechanisms connecting science, capital, regulation, procurement, and industrial adoption, innovation remains episodic. It generates technical activity without producing structural economic transformation.

From that perspective, this is becoming a more consequential competitive divide. The question is no longer simply which economies can fund innovation. It is which ones can govern it.

That distinction increasingly shapes industrial resilience, technological sovereignty, supply-chain redesign, and long-term competitiveness. For countries attempting to modernize under technological pressure, the decisive issue is whether innovation is built into the machinery of economic governance rather than left as a standalone policy agenda.